Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Bruce E Sands, Geert D’Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass

Open source

DOI: 10.1093/ibd/izae024
Published: 2024-03-09
Container: Inflammatory Bowel Diseases
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ibd/izae024,
  title = {Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study},
  author = {Bruce E Sands and Geert D’Haens and David B Clemow and Peter M Irving and Jordan T Johns and Theresa Hunter Gibble and Maria T Abreu and Scott Lee and Tadakazu Hisamatsu and Taku Kobayashi and Marla C Dubinsky and Severine Vermeire and Corey A Siegel and Laurent Peyrin-Biroulet and Richard E Moses and Joe Milata and Vipin Arora and Remo Panaccione and Axel Dignass},
  year = {2024},
  journal = {Inflammatory Bowel Diseases},
  doi = {10.1093/ibd/izae024},
  url = {https://doi.org/10.1093/ibd/izae024}
}

RIS

TY  - JOUR
TI  - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
AU  - Bruce E Sands
AU  - Geert D’Haens
AU  - David B Clemow
AU  - Peter M Irving
AU  - Jordan T Johns
AU  - Theresa Hunter Gibble
AU  - Maria T Abreu
AU  - Scott Lee
AU  - Tadakazu Hisamatsu
AU  - Taku Kobayashi
AU  - Marla C Dubinsky
AU  - Severine Vermeire
AU  - Corey A Siegel
AU  - Laurent Peyrin-Biroulet
AU  - Richard E Moses
AU  - Joe Milata
AU  - Vipin Arora
AU  - Remo Panaccione
AU  - Axel Dignass
PY  - 2024
JO  - Inflammatory Bowel Diseases
DO  - 10.1093/ibd/izae024
UR  - https://doi.org/10.1093/ibd/izae024
ER  -

APA

Sands, B. E., D’Haens, G., Clemow, D. B., Irving, P. M., Johns, J. T., Gibble, T. H., Abreu, M. T., Lee, S., Hisamatsu, T., Kobayashi, T., Dubinsky, M. C., Vermeire, S., Siegel, C. A., Peyrin-Biroulet, L., Moses, R. E., Milata, J., Arora, V., Panaccione, R., & Dignass, A. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae024

Source records

crossref · retrieved 2026-11-10T19:01:15.689Z